SEC Comment Letter for Cyclacel Pharmaceuticals, Inc. (BGMS, BGMSP) (CIK 0001130166) (BGMS) — May 25, 2010

Cyclacel Pharmaceuticals, Inc. (BGMS, BGMSP) (CIK 0001130166)
Date: May 25, 2010 · CIK: 0001130166 · Accession: 0000000000-10-028790

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 000-50626

Date

May 24, 2010

Author

Tabatha A kins

Form

UPLOAD

Company

Cyclacel Pharmaceuticals, Inc. (BGMS, BGMSP) (CIK 0001130166)

Letter

Via Facsimile and U.S. Mail Mail Stop 4720 May 24, 2010 Cyclacel Pharmaceuticals, Inc. Paul McBarron Executive Vice President —Finance, Chief Financial Officer and Chief Operating Officer 200 Connell Drive Suite 1500 Berkeley Heights, NJ 07922

Re: Cyclacel Pharmaceuticals, Inc. Item 4.02 Form 8 -K Filed May 13, 2010 File No. 000-50626

Dear Mr. McBarron :

We have completed our review of your Form 8-K and have no further comments at this time.

Sincerely,
Tabatha A kins
Staff Accountant

Show Raw Text

Via Facsimile and U.S. Mail
Mail Stop 4720

                                                                                                May 24, 2010

Cyclacel Pharmaceuticals, Inc.
Paul McBarron
Executive Vice President —Finance,  Chief Financial
Officer and  Chief Operating Officer
200 Connell Drive
Suite 1500
Berkeley Heights, NJ   07922

 Re: Cyclacel Pharmaceuticals, Inc.
 Item 4.02 Form 8 -K
Filed  May 13, 2010
 File No. 000-50626

Dear Mr. McBarron :

We have completed our review of your Form 8-K and have no further comments
at this time.

        Sincerely,

        Tabatha A kins
Staff Accountant

SecProbe.io